Dr Christopher Bacon Dr Christopher Carey
| Lymphoma triage from H&E using AI for improved clinical management | 2025 |
|
Dr Laura Jardine Dr Simone Webb Issac Goh Dr Gary Reynolds Dr Michael Mather et al. | Blood and immune development in human fetal bone marrow and Down syndrome | 2021 |
|
Dr Gary Reynolds Dr Peter Vegh Dr James Fletcher Dr Beth Poyner Dr Emily Stephenson et al. | Developmental cell programs are co-opted in inflammatory skin disease | 2021 |
|
Dr Meghan Acres Dr Gill Hulme Dr Christopher Carey Dr John Mansfield Emeritus Professor John Kirby et al. | Regulation and role of αE integrin and gut homing integrins in migration and retention of intestinal lymphocytes during inflammatory bowel disease | 2021 |
|
Sarah Armour Dr Scott Anderson Dr Yuchun Ding Dr Christopher Carey Dr Rashmi Maheshwari et al. | Reduced expression of the co-regulator TLE1 in type 2 diabetes is associated with increased islet α-cell number | 2020 |
|
Dr David Swan Professor Chris Lamb Dr Karin Engelhardt Dr Rui Chen Dr Yuchun Ding et al. | Immunodeficiency, autoimmune thrombocytopenia and enterocolitis caused by autosomal recessive deficiency of PIK3CD-encoded phosphoinositide 3-kinase δ | 2019 |
|
Dr Christopher Carey
| Adaptive Chromatin Remodeling Drives Glioblastoma Stem Cell Plasticity and Drug Tolerance. | 2017 |
|
Dr Christopher Carey
| Classical Hodgkin Lymphoma with Reduced β2M/MHC Class I Expression Is Associated with Inferior Outcome Independent of 9p24.1 Status | 2017 |
|
Dr Christopher Carey
| Diffuse Staining for Activated NOTCH1 Correlates With NOTCH1 Mutation Status and Is Associated With Worse Outcome in Adenoid Cystic Carcinoma | 2017 |
|
Dr Christopher Carey
| An oncogenic MYB feedback loop drives alternate cell fates in adenoid cystic carcinoma | 2016 |
|
Dr Christopher Carey Dr Rachel Crossland Dr Christopher Bacon Dr Vikki Rand
| Molecular Classification of MYC-Driven B-Cell Lymphomas by Targeted Gene Expression Profiling of Fixed Biopsy Specimens | 2015 |
|
Dr Christopher Carey
| Ganetespib (STA-9090), a Nongeldanamycin HSP90 Inhibitor, Has Potent Antitumor Activity in In Vitro and In Vivo Models of Non–Small Cell Lung Cancer | 2012 |
|